PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2501092

Haemodynamic studies with a phasic release nitroglycerin patch system.

M Bergbauer·K Weber
View original source ↗Export metadata ↓

Abstract

The use of transdermal nitroglycerin (GTN) patches in patients with coronary artery disease is of uncertain value as numerous investigators have failed to confirm clinical efficacy for more than 8h. This relatively short duration of action is an indication of rapidly developing tolerance due to the relatively constant GTN plasma levels following GTN patch application. We investigated the efficacy of a newly developed GTN patch with a discontinuous release profile in 28 patients with coronary heart disease. Two hours after initial administration, pulmonary capillary wedge (PCW) pressure decreased by 25.7% at rest and by 25.1% during exercise. Cardiac index at rest decreased by 12.2%. No significant changes were observed in systemic blood pressure and heart rate. No significant haemodynamic effects were apparent after 24h. Following renewed GTN patch application, a decrease in PCW pressure occurred, similar to that observed after acute administration. After 1 week of daily therapy, similar changes were observed: 24h after patch application, PCW was similar to baseline values but showed a significant decrease 2h after patch re-application. These data suggest that the phasic release GTN patch is not associated with tolerance to the haemodynamic effects during sustained once daily therapy.

Explore related subjects

Administration, CutaneousAdultAgedCoronary DiseaseDelayed-Action PreparationsDrug Administration ScheduleDrug ToleranceFemaleHemodynamicsHumansMaleMiddle AgedNitroglycerinJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Bergbauer, K Weber. 1989. Haemodynamic studies with a phasic release nitroglycerin patch system.. https://doi.org/10.1093/eurheartj%2F10.suppl_a.30

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate.

To evaluate the effect of transdermal sequential treatment with estradiol and estradiol/norethisterone acetate on lipoprotein metabolism, 25 postmenopausal women received treatment for 12 cycles of 4 weeks each (2 weeks estradiol 50 micrograms/day and 2 weeks a combined patch delivering norethisterone acetate 0.25 mg/day and estradiol 50 micrograms/day). Blood samples for lipoprotein analyses were drawn before treatment and in estrogen and combined phases in cycles 3 and 12. Plasma total cholesterol, low (LDL) and high (HDL) density lipoprotein were all significantly reduced in both estrogen and combined phases. Eighteen of the women continued the treatment for 36 cycles. In this group the HDL-cholesterol had returned to baseline values in combined phase in cycle 24. Plasma cholesterol and LDL-cholesterol values remained significantly reduced throughout the whole study compared to the pre-trial values. The present study by transdermal sequential hormonal treatment results in a lipid and lipoprotein pattern with reduced total cholesterol and LDL cholesterol in postmenopausal women.

Administration, Cutaneous↗
PubMed1992

Tolerance, rebound, and time-zero effect of nitrate therapy.

Both nitroglycerin and long-acting nitrates have proved effective in treating acute anginal pain. In recent years, however, development of tolerance with the continuous use of these agents has been documented. A pilot study demonstrated attenuation of the therapeutic effect of high-dose, continuous transdermal nitroglycerin therapy, despite adequate plasma nitroglycerin levels. In a subsequent, larger Transdermal Nitroglycerin Cooperative Study, evidence of tolerance was detected within 24 hours of initiation of continuous nitroglycerin patch therapy at several different dose levels. Sustained pharmacologic activity has been achieved with the intermittent use of transdermal nitroglycerin, usually for 12 hours followed by a 12-hour drug-free period. When the patch is discontinued, however, some patients experience exacerbation, or rebound, of anginal symptoms and a worsening of exercise tolerance at the end of the drug-free period. Additional clinical research is therefore needed to determine the optimal intermittent dosing strategy.

Administration, Cutaneous↗